Zymeworks gets FDA breakthrough therapy status for HER2-targeted bispecific antibody zanidatamab in patients with BTC
The FDA grants Breakthrough Therapy designation to new medicines…
Captare. Aestimare. Eligere. Succedere.
You are a Business
You are an Executive
Want to work at CAPTIS
Create and/or update
your confidential profile
Go to our Careers page
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News
Europe & International
+41 22 518 2100